Telix Pharmaceuticals (ASX:TLX) said the Brazilian Health Regulatory Agency approved its prostate cancer imaging agent Illuccix, according to a Tuesday Australian bourse filing.
The marketing authorization was granted to Telix's partner R2PHARMA, a unit of Grupo GSH. Telix provided Grupo GSH with an exclusive license to manufacture, distribute, and market Illuccix in Brazil, the filing said.
Telix and R2PHARMA will set up a joint venture, Telix Innovations Brazil, to commercialize and distribute Telix's therapeutic and diagnostic radiopharmaceutical products in Brazil. Telix Innovations Brazil will hold the exclusive license to commercialize and distribute Illuccix as well as future product candidates.
Illuccix, after radiolabeling with gallium-68, is a radioactive diagnostic agent used in conjunction with positron emission tomography to detect prostate-specific membrane antigen-positive lesions in men with prostate cancer.
It is already commercially available in Australia, Canada, New Zealand, as well as the US, and has recently been approved in the UK.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。